Statistics Collaborative - Design and analysis for biomedical research

PublicationsPublications

Janet Wittes

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8

  • Nosten F, Luxemburger C, Kyle D, Ballou W, Wittes J, Wah E, Chongsuphajaisiddhi T, Gordon D, White N, Sadoff J, Heppner DG, Group SSMVT. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Lancet 1996; 348:701-707.
  • Freedman L, Anderson G, Kipnis V, Prentice R, Wang C, Rossouw J, Wittes J, DeMets D. Approaches to monitoring the results of long-term disease prevention trials: examples from the women’s health initiative. Control Clin Trials 1996; 17:509-525.
  • The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. A Phase I study of recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis. Clin Neuropharmacol 1995; 18:515-532.
  • Ballou W, Blood J, Chongsuphajaissidhi T, Gordon D, Heppner D, Kyle D, Luxemburger C, Nosten F, Sadoff J, Singhasivanon P, White N, Webster K, Wittes J, Wongsrichanalai C. Field trials of an asexual blood stage malaria vaccine: studies of the synthetic peptide polymer SPf66 in Thailand and the analytic plan for a phase IIb efficacy study. Parasitology 1995; 110 Suppl:S25-S36.
  • Wittes J. Editorial. Control Clin Trials 1995; 1:1-2.
  • NIH Consensus Development Panel Members. Infectious disease testing for blood transfusions. NIH Consensus Statement. Bethesda: NIH, Vol. 13, 1-27, 1995.
    Reprinted: JAMA 1995; 274:1374-1379.
  • Wittes J, Wu M. Natural history of alpha-1AT deficiency. Chapter 18 of Crystal (ed). Alpha-1 Antitrypsin Deficiency: Biology - Pathogenesis - Clinical Manifestations - Therapy. New York: Marcel Dekker, 281-291, 1995.
  • Wittes J. Cross-national HRQOL measures: a statistical perspective. In S Shumaker et al. (eds). The International Assessment of Health-Related Quality of Life: Theory, Translation, Measurement & Analysis. New York: Rapid Communications, 159, 1995.
  • Lan K, Wittes J. Data monitoring in complex clinical trials: which treatment is “better”? J Stat Plan Infer 1994; 42:241-255.
  • Judd J, Clevidence B, Muesing R, Wittes J, Sunkin M, Podczasy J. Dietary trans fatty acids: effects on plasma lipids and lipoproteins of healthy men and women. Am J Clin Nutr 1994; 59:861-868.
  • Cowan C, Wittes J. Intercept studies, clinical trials, and cluster experiments: to whom can we extrapolate? Control Clin Trials 1994; 15:24-29.
  • Brown A, Singharaj P, Webster H, Pipithkul J, Gordon D, Boslego J, Krinchai K, Su-archawaratana P, Wongsrichanalai C, Ballou W, Permpanich B, Kain K, Hollingdale M, Wittes J, Que J, Gross M, Cryz S, Sadoff J. Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers. Vaccine 1994; 12:102-108.
  • Applegate W, Pressel S, Wittes J, Luhr J, Shekelle R, Camel G, Greenlick M, Hadley E, Moye L, Perry H, Schron E, Wegener V. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the Systolic Hypertension in the Elderly Program. Arch Intern Med 1994; 154:2154-2160.
  • Brittain E, Wittes J. Power trips: the factorial design for binary outcomes. Proceedings of the Biopharmaceutical Section of the American Statistical Association, Toronto Canada, 1994.
  • Wittes J, Singh B. Role of controlled clinical trials in drug evaluation. Chapter 3 in B Singh et al. (eds). Cardiovascular Pharmacology and Therapeutics. New York: Churchill Livingstone, 31-50, 1994.
  • Wittes J. Thoughts of an accidental entrepreneur. Can a Statistician Earn a Living on her Own? ASA Committee on Women in Statistics, 1994.
  • Wittes J. Behind closed doors: the data monitoring board in randomized clinical trials. Stat Med 1993; 12:419-424.
  • Wittes B, Wittes J. Group therapy. New Republic 1993; April 5:15-16.
  • Wallenstein S, Wittes J. The power of the Mantel-Haenszel test for grouped failure time data. Biometrics 1993; 49:1077-1087.
  • Rubins H, Robins S, Iwane M, Boden W, Elam M, Fye C, Gordon D, Schaefer E, Schectman G, Wittes J. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol 1993; 71:45-52.

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8